Device-Related Thrombus After Left Atrial Appendage Closure: Incidence, Predictors, and Outcomes

BACKGROUND:In patients with atrial fibrillation, left atrial appendage closure with the Watchman device prevents thromboembolism from the left atrial appendage; however, thrombus may form on the left atrial face of the device, and then potentially embolize. Herein, we studied the incidence, predicto...

Full description

Saved in:
Bibliographic Details
Published inCirculation (New York, N.Y.) Vol. 138; no. 9; pp. 874 - 885
Main Authors Dukkipati, Srinivas R., Kar, Saibal, Holmes, David R., Doshi, Shephal K., Swarup, Vijendra, Gibson, Douglas N., Maini, Brijeshwar, Gordon, Nicole T., Main, Michael L., Reddy, Vivek Y.
Format Journal Article
LanguageEnglish
Published United States by the American College of Cardiology Foundation and the American Heart Association, Inc 28.08.2018
Subjects
Online AccessGet full text
ISSN0009-7322
1524-4539
1524-4539
DOI10.1161/CIRCULATIONAHA.118.035090

Cover

Abstract BACKGROUND:In patients with atrial fibrillation, left atrial appendage closure with the Watchman device prevents thromboembolism from the left atrial appendage; however, thrombus may form on the left atrial face of the device, and then potentially embolize. Herein, we studied the incidence, predictors, and clinical outcome of device-related thrombus (DRT) using a large series of clinical trial cohorts of patients undergoing Watchman implantation. METHODS:We studied the device arms of 4 prospective Food and Drug Administration trialsPROTECT-AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation) (n=463); PREVAIL (Evaluation of the Watchman LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy) (n=269); CAP (Continued Access to PROTECT AF registry) (n=566); and CAP2 (Continued Access to PREVAIL registry) (n=578). Surveillance transesophageal echocardiographs were performed at 45 days and 12 months in all patients, and also at 6 months in the randomized control trials. We assessed both the incidence of DRT during these transesophageal echocardiographs (and other unscheduled transesophageal echocardiographs), and clinical outcomes of postprocedure stroke or systemic embolism (SSE) and adjusted for CHA2DS2-VASC and HAS-BLED scores. RESULTS:Of 1739 patients who received an implant (7159 patient-years follow-up; CHA2DS2-VASc=4.0), DRT was seen in 65 patients (3.74%). The rates of SSE with and without DRT were 7.46 and 1.78 per 100 patient-years (adjusted rate ratio, 3.55; 95% confidence interval [CI], 2.18–5.79; P<0.001), and ischemic SSE rates were 6.28 and 1.65 per 100 patient-years (adjusted rate ratio, 3.22; 95% CI, 1.90–5.45, P<0.001). On multivariable modeling analysis, the predictors of DRT were as followshistory of transient ischemic attack or stroke (odds ratio [OR], 2.31; 95% CI, 1.26–4.25; P=0.007), permanent atrial fibrillation (OR, 2.24; 95% CI, 1.19–4.20; P=0.012); vascular disease (OR, 2.06; 95% CI, 1.08–3.91; P=0.028); left atrial appendage diameter (OR, 1.06 per mm increase; 95% CI, 1.01–1.12; P=0.019); left ventricular ejection fraction (OR, 0.96 per 1% increase; 95% CI, 0.94–0.99; P=0.009). DRT and SSE both occurred in 17 of 65 patients (26.2%). Of the 19 SSE events in these patients with DRT, 9 of 19 (47.4%) and 12 of 19 (63.2%) occurred within 1 and 6 months of DRT detection. Conversely, after left atrial appendage closure, most SSEs (123/142, 86.62%) occurred in patients without DRT. CONCLUSIONS:After left atrial appendage closure with Watchman, DRT (≈3.7%) is not frequent but, when present, is associated with a higher rate of stroke and systemic embolism.
AbstractList In patients with atrial fibrillation, left atrial appendage closure with the Watchman device prevents thromboembolism from the left atrial appendage; however, thrombus may form on the left atrial face of the device, and then potentially embolize. Herein, we studied the incidence, predictors, and clinical outcome of device-related thrombus (DRT) using a large series of clinical trial cohorts of patients undergoing Watchman implantation. We studied the device arms of 4 prospective Food and Drug Administration trials: PROTECT-AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation) (n=463); PREVAIL (Evaluation of the Watchman LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy) (n=269); CAP (Continued Access to PROTECT AF registry) (n=566); and CAP2 (Continued Access to PREVAIL registry) (n=578). Surveillance transesophageal echocardiographs were performed at 45 days and 12 months in all patients, and also at 6 months in the randomized control trials. We assessed both the incidence of DRT during these transesophageal echocardiographs (and other unscheduled transesophageal echocardiographs), and clinical outcomes of postprocedure stroke or systemic embolism (SSE) and adjusted for CHA DS -VASC and HAS-BLED scores. Of 1739 patients who received an implant (7159 patient-years follow-up; CHA DS -VASc=4.0), DRT was seen in 65 patients (3.74%). The rates of SSE with and without DRT were 7.46 and 1.78 per 100 patient-years (adjusted rate ratio, 3.55; 95% confidence interval [CI], 2.18-5.79; P<0.001), and ischemic SSE rates were 6.28 and 1.65 per 100 patient-years (adjusted rate ratio, 3.22; 95% CI, 1.90-5.45, P<0.001). On multivariable modeling analysis, the predictors of DRT were as follows: history of transient ischemic attack or stroke (odds ratio [OR], 2.31; 95% CI, 1.26-4.25; P=0.007), permanent atrial fibrillation (OR, 2.24; 95% CI, 1.19-4.20; P=0.012); vascular disease (OR, 2.06; 95% CI, 1.08-3.91; P=0.028); left atrial appendage diameter (OR, 1.06 per mm increase; 95% CI, 1.01-1.12; P=0.019); left ventricular ejection fraction (OR, 0.96 per 1% increase; 95% CI, 0.94-0.99; P=0.009). DRT and SSE both occurred in 17 of 65 patients (26.2%). Of the 19 SSE events in these patients with DRT, 9 of 19 (47.4%) and 12 of 19 (63.2%) occurred within 1 and 6 months of DRT detection. Conversely, after left atrial appendage closure, most SSEs (123/142, 86.62%) occurred in patients without DRT. After left atrial appendage closure with Watchman, DRT (≈3.7%) is not frequent but, when present, is associated with a higher rate of stroke and systemic embolism.
BACKGROUND:In patients with atrial fibrillation, left atrial appendage closure with the Watchman device prevents thromboembolism from the left atrial appendage; however, thrombus may form on the left atrial face of the device, and then potentially embolize. Herein, we studied the incidence, predictors, and clinical outcome of device-related thrombus (DRT) using a large series of clinical trial cohorts of patients undergoing Watchman implantation. METHODS:We studied the device arms of 4 prospective Food and Drug Administration trialsPROTECT-AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation) (n=463); PREVAIL (Evaluation of the Watchman LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy) (n=269); CAP (Continued Access to PROTECT AF registry) (n=566); and CAP2 (Continued Access to PREVAIL registry) (n=578). Surveillance transesophageal echocardiographs were performed at 45 days and 12 months in all patients, and also at 6 months in the randomized control trials. We assessed both the incidence of DRT during these transesophageal echocardiographs (and other unscheduled transesophageal echocardiographs), and clinical outcomes of postprocedure stroke or systemic embolism (SSE) and adjusted for CHA2DS2-VASC and HAS-BLED scores. RESULTS:Of 1739 patients who received an implant (7159 patient-years follow-up; CHA2DS2-VASc=4.0), DRT was seen in 65 patients (3.74%). The rates of SSE with and without DRT were 7.46 and 1.78 per 100 patient-years (adjusted rate ratio, 3.55; 95% confidence interval [CI], 2.18–5.79; P<0.001), and ischemic SSE rates were 6.28 and 1.65 per 100 patient-years (adjusted rate ratio, 3.22; 95% CI, 1.90–5.45, P<0.001). On multivariable modeling analysis, the predictors of DRT were as followshistory of transient ischemic attack or stroke (odds ratio [OR], 2.31; 95% CI, 1.26–4.25; P=0.007), permanent atrial fibrillation (OR, 2.24; 95% CI, 1.19–4.20; P=0.012); vascular disease (OR, 2.06; 95% CI, 1.08–3.91; P=0.028); left atrial appendage diameter (OR, 1.06 per mm increase; 95% CI, 1.01–1.12; P=0.019); left ventricular ejection fraction (OR, 0.96 per 1% increase; 95% CI, 0.94–0.99; P=0.009). DRT and SSE both occurred in 17 of 65 patients (26.2%). Of the 19 SSE events in these patients with DRT, 9 of 19 (47.4%) and 12 of 19 (63.2%) occurred within 1 and 6 months of DRT detection. Conversely, after left atrial appendage closure, most SSEs (123/142, 86.62%) occurred in patients without DRT. CONCLUSIONS:After left atrial appendage closure with Watchman, DRT (≈3.7%) is not frequent but, when present, is associated with a higher rate of stroke and systemic embolism.
In patients with atrial fibrillation, left atrial appendage closure with the Watchman device prevents thromboembolism from the left atrial appendage; however, thrombus may form on the left atrial face of the device, and then potentially embolize. Herein, we studied the incidence, predictors, and clinical outcome of device-related thrombus (DRT) using a large series of clinical trial cohorts of patients undergoing Watchman implantation.BACKGROUNDIn patients with atrial fibrillation, left atrial appendage closure with the Watchman device prevents thromboembolism from the left atrial appendage; however, thrombus may form on the left atrial face of the device, and then potentially embolize. Herein, we studied the incidence, predictors, and clinical outcome of device-related thrombus (DRT) using a large series of clinical trial cohorts of patients undergoing Watchman implantation.We studied the device arms of 4 prospective Food and Drug Administration trials: PROTECT-AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation) (n=463); PREVAIL (Evaluation of the Watchman LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy) (n=269); CAP (Continued Access to PROTECT AF registry) (n=566); and CAP2 (Continued Access to PREVAIL registry) (n=578). Surveillance transesophageal echocardiographs were performed at 45 days and 12 months in all patients, and also at 6 months in the randomized control trials. We assessed both the incidence of DRT during these transesophageal echocardiographs (and other unscheduled transesophageal echocardiographs), and clinical outcomes of postprocedure stroke or systemic embolism (SSE) and adjusted for CHA2DS2-VASC and HAS-BLED scores.METHODSWe studied the device arms of 4 prospective Food and Drug Administration trials: PROTECT-AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation) (n=463); PREVAIL (Evaluation of the Watchman LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy) (n=269); CAP (Continued Access to PROTECT AF registry) (n=566); and CAP2 (Continued Access to PREVAIL registry) (n=578). Surveillance transesophageal echocardiographs were performed at 45 days and 12 months in all patients, and also at 6 months in the randomized control trials. We assessed both the incidence of DRT during these transesophageal echocardiographs (and other unscheduled transesophageal echocardiographs), and clinical outcomes of postprocedure stroke or systemic embolism (SSE) and adjusted for CHA2DS2-VASC and HAS-BLED scores.Of 1739 patients who received an implant (7159 patient-years follow-up; CHA2DS2-VASc=4.0), DRT was seen in 65 patients (3.74%). The rates of SSE with and without DRT were 7.46 and 1.78 per 100 patient-years (adjusted rate ratio, 3.55; 95% confidence interval [CI], 2.18-5.79; P<0.001), and ischemic SSE rates were 6.28 and 1.65 per 100 patient-years (adjusted rate ratio, 3.22; 95% CI, 1.90-5.45, P<0.001). On multivariable modeling analysis, the predictors of DRT were as follows: history of transient ischemic attack or stroke (odds ratio [OR], 2.31; 95% CI, 1.26-4.25; P=0.007), permanent atrial fibrillation (OR, 2.24; 95% CI, 1.19-4.20; P=0.012); vascular disease (OR, 2.06; 95% CI, 1.08-3.91; P=0.028); left atrial appendage diameter (OR, 1.06 per mm increase; 95% CI, 1.01-1.12; P=0.019); left ventricular ejection fraction (OR, 0.96 per 1% increase; 95% CI, 0.94-0.99; P=0.009). DRT and SSE both occurred in 17 of 65 patients (26.2%). Of the 19 SSE events in these patients with DRT, 9 of 19 (47.4%) and 12 of 19 (63.2%) occurred within 1 and 6 months of DRT detection. Conversely, after left atrial appendage closure, most SSEs (123/142, 86.62%) occurred in patients without DRT.RESULTSOf 1739 patients who received an implant (7159 patient-years follow-up; CHA2DS2-VASc=4.0), DRT was seen in 65 patients (3.74%). The rates of SSE with and without DRT were 7.46 and 1.78 per 100 patient-years (adjusted rate ratio, 3.55; 95% confidence interval [CI], 2.18-5.79; P<0.001), and ischemic SSE rates were 6.28 and 1.65 per 100 patient-years (adjusted rate ratio, 3.22; 95% CI, 1.90-5.45, P<0.001). On multivariable modeling analysis, the predictors of DRT were as follows: history of transient ischemic attack or stroke (odds ratio [OR], 2.31; 95% CI, 1.26-4.25; P=0.007), permanent atrial fibrillation (OR, 2.24; 95% CI, 1.19-4.20; P=0.012); vascular disease (OR, 2.06; 95% CI, 1.08-3.91; P=0.028); left atrial appendage diameter (OR, 1.06 per mm increase; 95% CI, 1.01-1.12; P=0.019); left ventricular ejection fraction (OR, 0.96 per 1% increase; 95% CI, 0.94-0.99; P=0.009). DRT and SSE both occurred in 17 of 65 patients (26.2%). Of the 19 SSE events in these patients with DRT, 9 of 19 (47.4%) and 12 of 19 (63.2%) occurred within 1 and 6 months of DRT detection. Conversely, after left atrial appendage closure, most SSEs (123/142, 86.62%) occurred in patients without DRT.After left atrial appendage closure with Watchman, DRT (≈3.7%) is not frequent but, when present, is associated with a higher rate of stroke and systemic embolism.CONCLUSIONSAfter left atrial appendage closure with Watchman, DRT (≈3.7%) is not frequent but, when present, is associated with a higher rate of stroke and systemic embolism.
Author Gordon, Nicole T.
Kar, Saibal
Dukkipati, Srinivas R.
Holmes, David R.
Gibson, Douglas N.
Reddy, Vivek Y.
Swarup, Vijendra
Main, Michael L.
Doshi, Shephal K.
Maini, Brijeshwar
AuthorAffiliation Icahn School of Medicine at Mount Sinai, New York, NY (S.R.D., V.Y.R.) Cedars Sinai Medical Center, Los Angeles, CA (S.K.) Mayo Clinic, Rochester, MN (D.R.H.) Pacific Heart Institute, Santa Monica, CA (S.K.D.) Arizona Heart Rhythm Center, Phoenix (V.S.) Scripps Clinic, La Jolla, CA (D.N.G.) Delray Medical, Delray Beach, FL (B.M.) Boston Scientific Corporation, St. Paul, MN (N.T.G.) University of Missouri-Kansas City (M.L.M.)
AuthorAffiliation_xml – name: Icahn School of Medicine at Mount Sinai, New York, NY (S.R.D., V.Y.R.) Cedars Sinai Medical Center, Los Angeles, CA (S.K.) Mayo Clinic, Rochester, MN (D.R.H.) Pacific Heart Institute, Santa Monica, CA (S.K.D.) Arizona Heart Rhythm Center, Phoenix (V.S.) Scripps Clinic, La Jolla, CA (D.N.G.) Delray Medical, Delray Beach, FL (B.M.) Boston Scientific Corporation, St. Paul, MN (N.T.G.) University of Missouri-Kansas City (M.L.M.)
Author_xml – sequence: 1
  givenname: Srinivas
  surname: Dukkipati
  middlename: R.
  fullname: Dukkipati, Srinivas R.
  organization: Icahn School of Medicine at Mount Sinai, New York, NY (S.R.D., V.Y.R.) Cedars Sinai Medical Center, Los Angeles, CA (S.K.) Mayo Clinic, Rochester, MN (D.R.H.) Pacific Heart Institute, Santa Monica, CA (S.K.D.) Arizona Heart Rhythm Center, Phoenix (V.S.) Scripps Clinic, La Jolla, CA (D.N.G.) Delray Medical, Delray Beach, FL (B.M.) Boston Scientific Corporation, St. Paul, MN (N.T.G.) University of Missouri-Kansas City (M.L.M.)
– sequence: 2
  givenname: Saibal
  surname: Kar
  fullname: Kar, Saibal
– sequence: 3
  givenname: David
  surname: Holmes
  middlename: R.
  fullname: Holmes, David R.
– sequence: 4
  givenname: Shephal
  surname: Doshi
  middlename: K.
  fullname: Doshi, Shephal K.
– sequence: 5
  givenname: Vijendra
  surname: Swarup
  fullname: Swarup, Vijendra
– sequence: 6
  givenname: Douglas
  surname: Gibson
  middlename: N.
  fullname: Gibson, Douglas N.
– sequence: 7
  givenname: Brijeshwar
  surname: Maini
  fullname: Maini, Brijeshwar
– sequence: 8
  givenname: Nicole
  surname: Gordon
  middlename: T.
  fullname: Gordon, Nicole T.
– sequence: 9
  givenname: Michael
  surname: Main
  middlename: L.
  fullname: Main, Michael L.
– sequence: 10
  givenname: Vivek
  surname: Reddy
  middlename: Y.
  fullname: Reddy, Vivek Y.
BackLink https://www.ncbi.nlm.nih.gov/pubmed/29752398$$D View this record in MEDLINE/PubMed
BookMark eNqNkUtv1DAUhS1URKeFv4DMjkVT_MrDSKiKwqMjjRhUTdfGca4ZgxMPtkPFvydo2gWsurq6R985V7rnDJ1MYQKEXlFySWlF33Trm-520-7W28_tdbtozSXhJZHkCVrRkolClFyeoBUhRBY1Z-wUnaX0fVkrXpfP0CmTdcm4bFbo63v45QwUN-B1hgHv9jGM_ZxwazNEvAGbcZuj0x63hwNMg_4GuPMhzRHe4vVk3ACTgQv8JcLgTA4xXWA9DXg7ZxNGSM_RU6t9ghf38xzdfvyw666LzfbTums3heE1JYVmljAp-4EL0lsOpgbLBJNUaGoMNFaURMDAuK5ZbUpr-opVklqw0JPGWn6OXh9zDzH8nCFlNbpkwHs9QZiTYoQ3rGqEFAv68h6d-xEGdYhu1PG3evjKAlwdARNDShGsMi7r7MKUo3ZeUaL-9qD-7WHRGnXsYUmQ_yU8HHmM993Rexf80kH64ec7iGoP2uf9I_x_AGjfoiU
CitedBy_id crossref_primary_10_1007_s10840_020_00884_x
crossref_primary_10_1111_pace_14448
crossref_primary_10_1007_s00392_022_02151_7
crossref_primary_10_1016_j_cjca_2025_03_018
crossref_primary_10_1007_s12928_022_00852_4
crossref_primary_10_1161_JAHA_123_032974
crossref_primary_10_1002_ehf2_12435
crossref_primary_10_1016_j_jacep_2018_09_007
crossref_primary_10_1016_j_jacep_2018_10_018
crossref_primary_10_1007_s10840_020_00819_6
crossref_primary_10_1016_j_jacep_2022_07_014
crossref_primary_10_1016_j_jcin_2021_11_023
crossref_primary_10_4244_EIJ_D_21_01010
crossref_primary_10_1186_s12872_023_03651_8
crossref_primary_10_1016_j_hroo_2021_06_004
crossref_primary_10_1016_j_iccl_2023_08_007
crossref_primary_10_1111_pace_14201
crossref_primary_10_4244_EIJ_D_21_00286
crossref_primary_10_1016_j_jcct_2020_03_003
crossref_primary_10_1002_advs_202401301
crossref_primary_10_1016_j_jaccao_2022_10_016
crossref_primary_10_1016_j_jjcc_2022_01_004
crossref_primary_10_1161_CIRCULATIONAHA_118_036179
crossref_primary_10_1161_CIRCULATIONAHA_118_035764
crossref_primary_10_1016_j_acvd_2020_08_001
crossref_primary_10_7326_AITC202307180
crossref_primary_10_1016_j_jacep_2021_05_009
crossref_primary_10_1016_j_cjco_2024_05_015
crossref_primary_10_1016_j_jamda_2023_06_016
crossref_primary_10_1093_ehjcr_ytae438
crossref_primary_10_1016_j_jacc_2019_08_1045
crossref_primary_10_1007_s10840_021_00958_4
crossref_primary_10_1016_j_jaccao_2023_03_004
crossref_primary_10_1002_ccd_29458
crossref_primary_10_1016_j_jcin_2023_06_022
crossref_primary_10_1093_ehjci_jeac222
crossref_primary_10_1161_CIRCULATIONAHA_119_040860
crossref_primary_10_1002_adem_201901074
crossref_primary_10_1016_j_ccep_2023_01_011
crossref_primary_10_1097_HCO_0000000000000698
crossref_primary_10_1007_s11886_024_02132_4
crossref_primary_10_29001_2073_8552_2023_38_4_46_54
crossref_primary_10_1161_CIRCINTERVENTIONS_123_013750
crossref_primary_10_1002_joa3_12649
crossref_primary_10_1016_j_ccep_2019_10_002
crossref_primary_10_1016_j_ccep_2019_10_003
crossref_primary_10_7759_cureus_47444
crossref_primary_10_3389_fbioe_2022_1021827
crossref_primary_10_1016_j_ccl_2019_01_009
crossref_primary_10_1080_24748706_2021_1890286
crossref_primary_10_1016_j_ijcha_2020_100688
crossref_primary_10_1097_MS9_0000000000001735
crossref_primary_10_1007_s00392_022_02065_4
crossref_primary_10_1016_j_jaccas_2023_101933
crossref_primary_10_1016_j_cjco_2024_09_011
crossref_primary_10_1016_j_jcin_2021_07_031
crossref_primary_10_1055_a_1387_6146
crossref_primary_10_1007_s00392_023_02237_w
crossref_primary_10_1161_CIR_0000000000001193
crossref_primary_10_1016_j_jcis_2020_10_051
crossref_primary_10_1016_j_jcin_2021_08_064
crossref_primary_10_1007_s10840_021_01073_0
crossref_primary_10_1097_HCO_0000000000001091
crossref_primary_10_3390_jcm13040939
crossref_primary_10_1080_17434440_2020_1781615
crossref_primary_10_7759_cureus_24073
crossref_primary_10_1161_CIRCINTERVENTIONS_122_012812
crossref_primary_10_4244_EIJ_D_20_00886
crossref_primary_10_1016_j_jcin_2020_06_056
crossref_primary_10_1080_24748706_2020_1834173
crossref_primary_10_1080_14796678_2024_2363063
crossref_primary_10_1007_s11886_018_1052_1
crossref_primary_10_1155_2021_9195984
crossref_primary_10_1093_europace_euz258
crossref_primary_10_1093_europace_euaa065
crossref_primary_10_1161_CIRCULATIONAHA_121_054305
crossref_primary_10_1016_j_jscai_2022_100577
crossref_primary_10_1007_s00392_023_02228_x
crossref_primary_10_17106_jbr_36_31
crossref_primary_10_3389_fcvm_2022_853299
crossref_primary_10_3995_jstroke_11248
crossref_primary_10_1016_j_hrthm_2020_05_004
crossref_primary_10_2459_JCM_0000000000001394
crossref_primary_10_1097_CRD_0000000000000757
crossref_primary_10_1007_s11936_022_00958_1
crossref_primary_10_1007_s10840_024_01914_8
crossref_primary_10_1021_acs_chemrev_2c00005
crossref_primary_10_1161_STROKEAHA_123_040447
crossref_primary_10_1111_pace_13796
crossref_primary_10_3390_jcm13164651
crossref_primary_10_1016_j_case_2023_01_010
crossref_primary_10_1016_j_rec_2023_06_020
crossref_primary_10_1016_j_ccep_2023_01_004
crossref_primary_10_1089_3dp_2022_0373
crossref_primary_10_1016_j_ccep_2023_01_006
crossref_primary_10_1016_j_ccep_2023_01_005
crossref_primary_10_31083_j_rcm2512450
crossref_primary_10_1080_14779072_2020_1794820
crossref_primary_10_1093_europace_euaa074
crossref_primary_10_3389_fneur_2021_784557
crossref_primary_10_1016_j_jaccas_2022_07_037
crossref_primary_10_3389_fcvm_2019_00075
crossref_primary_10_1016_j_rec_2018_12_005
crossref_primary_10_1111_pace_13681
crossref_primary_10_1016_j_cjca_2019_01_015
crossref_primary_10_1016_j_hrthm_2019_09_018
crossref_primary_10_1111_pace_13683
crossref_primary_10_31083_j_rcm2502060
crossref_primary_10_3390_jpm12091413
crossref_primary_10_1016_j_chest_2018_07_040
crossref_primary_10_1016_j_jcin_2019_04_004
crossref_primary_10_1161_CIRCEP_118_006841
crossref_primary_10_1016_j_jacep_2019_07_011
crossref_primary_10_1161_JAHA_121_027001
crossref_primary_10_2459_JCM_0000000000001610
crossref_primary_10_1016_j_ccep_2019_11_008
crossref_primary_10_1016_j_ccep_2019_11_005
crossref_primary_10_1016_j_hrthm_2023_01_007
crossref_primary_10_1055_a_1953_0255
crossref_primary_10_1161_CIRCINTERVENTIONS_120_010195
crossref_primary_10_1097_FJC_0000000000001064
crossref_primary_10_1016_j_mtbio_2022_100240
crossref_primary_10_1007_s12181_020_00441_w
crossref_primary_10_1055_a_2469_4896
crossref_primary_10_7759_cureus_74577
crossref_primary_10_1016_j_carrev_2022_10_002
crossref_primary_10_1016_j_recesp_2018_11_024
crossref_primary_10_1111_echo_15722
crossref_primary_10_1080_17843286_2020_1821494
crossref_primary_10_1016_j_pcad_2021_11_013
crossref_primary_10_1111_jce_14398
crossref_primary_10_1002_ccd_27774
crossref_primary_10_1159_000509277
crossref_primary_10_1001_jamacardio_2024_1571
crossref_primary_10_1093_europace_euz161
crossref_primary_10_2169_naika_111_1687
crossref_primary_10_1016_j_jacep_2019_07_008
crossref_primary_10_1186_s12872_021_02059_6
crossref_primary_10_1002_ccd_31111
crossref_primary_10_1111_jce_14838
crossref_primary_10_2302_kjm_2023_0017_CR
crossref_primary_10_1186_s12872_024_04383_z
crossref_primary_10_23736_S0026_4806_21_07525_X
crossref_primary_10_1177_10760296211005033
crossref_primary_10_1016_j_hjc_2024_03_002
crossref_primary_10_1097_FJC_0000000000000786
crossref_primary_10_1161_CIRCINTERVENTIONS_119_008481
crossref_primary_10_7759_cureus_63442
crossref_primary_10_37615_retic_v4n3a13
crossref_primary_10_1007_s11239_020_02205_5
crossref_primary_10_1148_rg_2021200136
crossref_primary_10_1016_j_iccl_2021_11_011
crossref_primary_10_1016_j_jacc_2021_04_098
crossref_primary_10_1053_j_jvca_2019_01_049
crossref_primary_10_1093_eurheartj_ehaa169
crossref_primary_10_1186_s12872_019_1123_2
crossref_primary_10_1002_ccd_28530
crossref_primary_10_1016_j_ccep_2020_04_007
crossref_primary_10_1186_s40360_024_00834_7
crossref_primary_10_1016_j_hrthm_2024_11_035
crossref_primary_10_1016_j_jcin_2020_07_043
crossref_primary_10_1080_14779072_2022_2043745
crossref_primary_10_1016_j_hrthm_2022_06_001
crossref_primary_10_1016_j_jcin_2023_05_045
crossref_primary_10_1016_j_jacadv_2022_100136
crossref_primary_10_1186_s12872_022_02731_5
crossref_primary_10_1111_pace_14284
crossref_primary_10_1111_jce_14182
crossref_primary_10_1002_clc_23956
crossref_primary_10_4244_EIJ_D_21_00320
crossref_primary_10_1111_pace_14049
crossref_primary_10_1016_j_jstrokecerebrovasdis_2024_107618
crossref_primary_10_3389_fcvm_2023_1018877
crossref_primary_10_1111_jce_14053
crossref_primary_10_1007_s00380_020_01760_4
crossref_primary_10_1161_CIRCINTERVENTIONS_121_011718
crossref_primary_10_1002_joa3_12691
crossref_primary_10_1016_j_iccl_2021_11_006
crossref_primary_10_1016_j_iccl_2021_11_009
crossref_primary_10_1016_j_iccl_2021_11_008
crossref_primary_10_1016_j_jaccas_2020_05_096
crossref_primary_10_1016_j_jscai_2022_100405
crossref_primary_10_1016_j_jacep_2024_10_024
crossref_primary_10_17925_HI_2023_17_1_54
crossref_primary_10_3390_jcm14061787
crossref_primary_10_1148_radiol_230462
crossref_primary_10_1097_CRD_0000000000000601
crossref_primary_10_7759_cureus_69286
crossref_primary_10_1002_joa3_12338
crossref_primary_10_1253_circj_CJ_20_0196
crossref_primary_10_1016_j_jacc_2021_10_022
crossref_primary_10_1159_000513901
crossref_primary_10_3390_jcm12237292
crossref_primary_10_1177_15569845231163857
crossref_primary_10_1007_s10840_021_01080_1
crossref_primary_10_1080_08998280_2023_2269354
crossref_primary_10_1161_CIRCEP_118_007142
crossref_primary_10_7759_cureus_10077
crossref_primary_10_1016_j_hrthm_2020_06_024
crossref_primary_10_15420_icr_2018_21_3
crossref_primary_10_1055_s_0041_1726332
crossref_primary_10_1016_j_jaccas_2020_03_010
crossref_primary_10_1111_jce_14889
crossref_primary_10_1016_j_hrthm_2021_04_024
crossref_primary_10_1093_europace_euaa001
crossref_primary_10_1007_s13670_024_00422_x
crossref_primary_10_1016_j_avsurg_2022_100146
crossref_primary_10_1016_j_jcin_2024_04_050
crossref_primary_10_1007_s11886_020_01357_3
crossref_primary_10_1016_j_jjcc_2023_09_010
crossref_primary_10_1016_j_recesp_2023_06_005
crossref_primary_10_1016_j_jacep_2021_11_015
crossref_primary_10_1016_j_jcin_2023_10_046
crossref_primary_10_1016_j_jjcc_2025_01_014
crossref_primary_10_1016_j_jcin_2023_01_008
crossref_primary_10_4244_EIJ_D_22_00627
crossref_primary_10_1016_j_hlc_2024_02_010
crossref_primary_10_1253_circj_CJ_20_0640
crossref_primary_10_1016_j_jcin_2023_01_011
crossref_primary_10_1016_j_ijcard_2021_09_051
crossref_primary_10_1016_j_jaccas_2024_103219
crossref_primary_10_1038_s41467_025_57146_5
crossref_primary_10_1161_CIRCIMAGING_122_014804
crossref_primary_10_1016_j_hrcr_2021_06_008
crossref_primary_10_1016_j_ijcard_2020_11_045
crossref_primary_10_1053_j_jvca_2019_01_054
crossref_primary_10_1161_CIRCULATIONAHA_120_050117
crossref_primary_10_1053_j_ro_2023_11_003
crossref_primary_10_1016_j_jcin_2023_10_030
crossref_primary_10_1007_s13239_025_00773_2
crossref_primary_10_35336_VA_2023_2_07
crossref_primary_10_7759_cureus_26892
crossref_primary_10_1016_j_jcin_2023_09_017
crossref_primary_10_1016_j_jacasi_2022_04_009
crossref_primary_10_1016_j_jacc_2022_02_047
crossref_primary_10_1007_s00392_020_01623_y
crossref_primary_10_1016_j_jcin_2022_02_029
crossref_primary_10_1016_j_jjcc_2020_04_007
crossref_primary_10_1186_s12872_022_02865_6
crossref_primary_10_1016_j_hrcr_2023_11_003
crossref_primary_10_1080_24748706_2020_1766162
crossref_primary_10_1253_circj_CJ_22_0687
crossref_primary_10_1111_echo_15476
crossref_primary_10_1007_s12928_022_00839_1
crossref_primary_10_1093_ehjcr_ytae135
crossref_primary_10_1253_circj_CJ_21_0162
crossref_primary_10_1007_s10840_019_00678_w
crossref_primary_10_1111_jce_15999
crossref_primary_10_1016_j_shj_2024_100354
crossref_primary_10_3390_diagnostics13213325
crossref_primary_10_1186_s12872_024_04094_5
crossref_primary_10_1111_pace_14122
crossref_primary_10_1093_eurheartj_ehaa803
crossref_primary_10_1016_j_jcin_2019_02_003
crossref_primary_10_1161_CIRCINTERVENTIONS_120_009039
crossref_primary_10_1016_j_jacc_2022_04_062
crossref_primary_10_1016_j_jjcc_2021_08_031
crossref_primary_10_3389_fcvm_2022_1088782
crossref_primary_10_3390_jcm13030803
crossref_primary_10_1080_24748706_2021_1900631
crossref_primary_10_3390_biomedicines10092268
crossref_primary_10_1007_s11936_019_0767_7
crossref_primary_10_1016_j_jacep_2022_01_014
crossref_primary_10_1093_eurheartj_ehae398
crossref_primary_10_3389_fcvm_2022_1080257
crossref_primary_10_1007_s00380_024_02427_0
crossref_primary_10_1097_HCO_0000000000000818
crossref_primary_10_3390_jcm13226899
crossref_primary_10_1016_j_jacep_2022_11_029
crossref_primary_10_1002_app_51277
crossref_primary_10_1016_j_jacep_2021_04_012
crossref_primary_10_1097_FJC_0000000000001215
crossref_primary_10_1016_j_case_2024_05_007
crossref_primary_10_1016_j_jtcvs_2018_10_074
crossref_primary_10_3389_fcvm_2020_00011
crossref_primary_10_1016_j_jcin_2019_03_039
crossref_primary_10_1016_j_jcin_2022_02_009
crossref_primary_10_17925_EJAE_2019_5_1_40
crossref_primary_10_1155_2024_4405152
crossref_primary_10_1177_00368504221113194
crossref_primary_10_1148_radiol_231828
crossref_primary_10_1177_15569845241311301
crossref_primary_10_1016_j_jacc_2023_08_017
crossref_primary_10_1093_ehjcr_ytab517
crossref_primary_10_1016_j_hrcr_2021_01_014
crossref_primary_10_3390_jcm12030847
crossref_primary_10_4244_EIJY19M08_01
crossref_primary_10_1016_j_athoracsur_2024_02_012
crossref_primary_10_1016_j_hrthm_2024_05_016
crossref_primary_10_1016_j_jacep_2019_11_009
crossref_primary_10_3389_fcvm_2022_1023941
crossref_primary_10_1016_j_jcin_2021_12_022
crossref_primary_10_1161_CIRCULATIONAHA_118_036037
crossref_primary_10_1038_s41569_024_01076_0
crossref_primary_10_1093_eurheartj_ehae176
crossref_primary_10_3389_fphar_2024_1344828
crossref_primary_10_1136_heartjnl_2019_314898
crossref_primary_10_4244_EIJ_D_24_00116
crossref_primary_10_1007_s11886_019_1151_7
crossref_primary_10_1016_j_thromres_2022_05_009
crossref_primary_10_1016_j_amjcard_2020_08_013
crossref_primary_10_1007_s00392_021_01874_3
crossref_primary_10_1007_s11886_020_01387_x
crossref_primary_10_1016_j_hrcr_2024_01_008
crossref_primary_10_1002_ccr3_8113
crossref_primary_10_1161_CIRCEP_119_007257
crossref_primary_10_15420_aer_2019_8_2_FO1
crossref_primary_10_3389_fbioe_2023_1011121
crossref_primary_10_1016_j_hrthm_2019_12_004
crossref_primary_10_1016_j_jacc_2021_05_028
crossref_primary_10_1016_j_jacc_2018_05_028
Cites_doi 10.1093/eurheartj/ehr488
10.1001/jama.2014.15192
10.1016/j.jacc.2017.10.021
10.1016/j.hrthm.2017.05.038
10.1016/j.jacc.2018.01.076
10.1160/TH11-05-0364
10.1016/j.jacc.2015.04.025
10.1161/CIRCULATIONAHA.110.976449
10.4244/EIJ-D-17-00672
10.1007/s00380-017-0971-x
10.1016/S0140-6736(09)61343-X
10.4244/EIJ-D-17-00042
10.1161/CIRCINTERVENTIONS.117.005997
10.1002/ccd.26903
10.1016/j.amjcard.2016.01.039
10.1016/j.jacep.2017.05.006
10.1016/j.hrthm.2016.10.020
10.1016/j.jacc.2014.04.029
10.1016/j.jcin.2016.11.029
10.1161/CIRCULATIONAHA.112.114389
ContentType Journal Article
Copyright 2018 by the American College of Cardiology Foundation and the American Heart Association, Inc.
Copyright_xml – notice: 2018 by the American College of Cardiology Foundation and the American Heart Association, Inc.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1161/CIRCULATIONAHA.118.035090
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Anatomy & Physiology
EISSN 1524-4539
EndPage 885
ExternalDocumentID 29752398
10_1161_CIRCULATIONAHA_118_035090
10.1161/CIRCULATIONAHA.118.035090
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
.-D
.3C
.XZ
.Z2
01R
0R~
0ZK
18M
1J1
29B
2FS
2WC
354
40H
4Q1
4Q2
4Q3
53G
5GY
5RE
5VS
6PF
71W
77Y
7O~
AAAAV
AAAXR
AAGIX
AAHPQ
AAIQE
AAJCS
AAMOA
AAMTA
AAQKA
AARTV
AASCR
AASOK
AASXQ
AAUEB
AAWTL
AAXQO
ABASU
ABBUW
ABDIG
ABJNI
ABOCM
ABPMR
ABPXF
ABQRW
ABVCZ
ABXVJ
ABXYN
ABZAD
ABZZY
ACCJW
ACDDN
ACDOF
ACEWG
ACGFO
ACGFS
ACILI
ACLDA
ACOAL
ACRKK
ACWDW
ACWRI
ACXJB
ACXNZ
ACZKN
ADBBV
ADCYY
ADGGA
ADHPY
AE3
AE6
AEBDS
AEETU
AENEX
AFBFQ
AFCHL
AFDTB
AFEXH
AFMBP
AFNMH
AFSOK
AFUWQ
AGINI
AHMBA
AHOMT
AHQNM
AHQVU
AHRYX
AHVBC
AIJEX
AINUH
AJCLO
AJIOK
AJNWD
AJZMW
AKCTQ
AKULP
ALKUP
ALMA_UNASSIGNED_HOLDINGS
ALMTX
AMJPA
AMKUR
AMNEI
AOHHW
AOQMC
ASPBG
AVWKF
AYCSE
AZFZN
BAWUL
BOYCO
BQLVK
BYPQX
C45
CS3
DIK
DIWNM
DU5
E3Z
EBS
EEVPB
EJD
ERAAH
EX3
F2K
F2L
F2M
F2N
F5P
FCALG
GNXGY
GQDEL
GX1
H0~
HLJTE
HZ~
IKREB
IKYAY
IN~
IPNFZ
JF9
JG8
JK3
K-A
K-F
K8S
KD2
KMI
KQ8
L-C
L7B
N9A
N~7
N~B
O9-
OAG
OAH
OBH
OCB
ODMTH
OGEVE
OHH
OHYEH
OK1
OL1
OLB
OLG
OLH
OLU
OLV
OLY
OLZ
OPUJH
OVD
OVDNE
OVIDH
OVLEI
OVOZU
OWBYB
OWU
OWV
OWW
OWX
OWY
OWZ
OXXIT
P2P
PQQKQ
RAH
RIG
RLZ
S4R
S4S
T8P
TEORI
TR2
TSPGW
UPT
V2I
VVN
W2D
W3M
W8F
WH7
WOQ
WOW
X3V
X3W
XXN
XYM
YFH
YOC
YSK
YYM
YZZ
ZFV
ZY1
~H1
AAFWJ
AAYXX
CITATION
ACIJW
AWKKM
CGR
CUY
CVF
ECM
EIF
NPM
ODA
OJAPA
OLW
RHF
7X8
ADKSD
ADSXY
ID FETCH-LOGICAL-c3710-a2f0299bd340bf3ec7ef242914a1cce8f4504ed23a727c5fcb62691fefeb08ff3
ISSN 0009-7322
1524-4539
IngestDate Mon Sep 08 02:35:33 EDT 2025
Wed Feb 19 02:31:27 EST 2025
Thu Apr 24 23:04:17 EDT 2025
Tue Jul 01 03:21:05 EDT 2025
Fri May 16 03:49:59 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 9
Keywords atrial fibrillation
percutaneous coronary intervention
thrombosis
stroke
atrial appendage
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c3710-a2f0299bd340bf3ec7ef242914a1cce8f4504ed23a727c5fcb62691fefeb08ff3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 29752398
PQID 2038268494
PQPubID 23479
PageCount 12
ParticipantIDs proquest_miscellaneous_2038268494
pubmed_primary_29752398
crossref_citationtrail_10_1161_CIRCULATIONAHA_118_035090
crossref_primary_10_1161_CIRCULATIONAHA_118_035090
wolterskluwer_health_10_1161_CIRCULATIONAHA_118_035090
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2018-August-28
PublicationDateYYYYMMDD 2018-08-28
PublicationDate_xml – month: 08
  year: 2018
  text: 2018-August-28
  day: 28
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Circulation (New York, N.Y.)
PublicationTitleAlternate Circulation
PublicationYear 2018
Publisher by the American College of Cardiology Foundation and the American Heart Association, Inc
Publisher_xml – name: by the American College of Cardiology Foundation and the American Heart Association, Inc
References e_1_3_3_6_2
e_1_3_3_5_2
e_1_3_3_8_2
e_1_3_3_7_2
e_1_3_3_17_2
e_1_3_3_9_2
e_1_3_3_16_2
e_1_3_3_19_2
e_1_3_3_18_2
e_1_3_3_13_2
e_1_3_3_12_2
e_1_3_3_15_2
e_1_3_3_14_2
e_1_3_3_2_2
e_1_3_3_20_2
e_1_3_3_4_2
e_1_3_3_11_2
e_1_3_3_22_2
e_1_3_3_3_2
e_1_3_3_10_2
e_1_3_3_21_2
30857396 - Circulation. 2019 Feb 26;139(9):1241-1242
30354457 - Circulation. 2018 Aug 28;138(9):886-888
32011833 - Circulation. 2019 Feb 26;139(9):1240
References_xml – ident: e_1_3_3_21_2
  doi: 10.1093/eurheartj/ehr488
– ident: e_1_3_3_3_2
  doi: 10.1001/jama.2014.15192
– ident: e_1_3_3_2_2
  doi: 10.1016/j.jacc.2017.10.021
– ident: e_1_3_3_12_2
  doi: 10.1016/j.hrthm.2017.05.038
– ident: e_1_3_3_19_2
  doi: 10.1016/j.jacc.2018.01.076
– ident: e_1_3_3_22_2
  doi: 10.1160/TH11-05-0364
– ident: e_1_3_3_5_2
  doi: 10.1016/j.jacc.2015.04.025
– ident: e_1_3_3_17_2
  doi: 10.1161/CIRCULATIONAHA.110.976449
– ident: e_1_3_3_8_2
  doi: 10.4244/EIJ-D-17-00672
– ident: e_1_3_3_20_2
  doi: 10.1007/s00380-017-0971-x
– ident: e_1_3_3_15_2
– ident: e_1_3_3_6_2
  doi: 10.1016/S0140-6736(09)61343-X
– ident: e_1_3_3_13_2
  doi: 10.4244/EIJ-D-17-00042
– ident: e_1_3_3_11_2
  doi: 10.1161/CIRCINTERVENTIONS.117.005997
– ident: e_1_3_3_9_2
  doi: 10.1002/ccd.26903
– ident: e_1_3_3_7_2
  doi: 10.1016/j.amjcard.2016.01.039
– ident: e_1_3_3_14_2
  doi: 10.1016/j.jacep.2017.05.006
– ident: e_1_3_3_18_2
  doi: 10.1016/j.hrthm.2016.10.020
– ident: e_1_3_3_16_2
  doi: 10.1016/j.jacc.2014.04.029
– ident: e_1_3_3_10_2
  doi: 10.1016/j.jcin.2016.11.029
– ident: e_1_3_3_4_2
  doi: 10.1161/CIRCULATIONAHA.112.114389
– reference: 30354457 - Circulation. 2018 Aug 28;138(9):886-888
– reference: 30857396 - Circulation. 2019 Feb 26;139(9):1241-1242
– reference: 32011833 - Circulation. 2019 Feb 26;139(9):1240
SSID ssj0006375
Score 2.6661084
Snippet BACKGROUND:In patients with atrial fibrillation, left atrial appendage closure with the Watchman device prevents thromboembolism from the left atrial...
In patients with atrial fibrillation, left atrial appendage closure with the Watchman device prevents thromboembolism from the left atrial appendage; however,...
SourceID proquest
pubmed
crossref
wolterskluwer
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 874
SubjectTerms Aged
Aged, 80 and over
Atrial Appendage - diagnostic imaging
Atrial Appendage - physiopathology
Atrial Fibrillation - diagnosis
Atrial Fibrillation - epidemiology
Atrial Fibrillation - physiopathology
Atrial Fibrillation - therapy
Atrial Function, Left
Cardiac Catheterization - adverse effects
Cardiac Catheterization - instrumentation
Echocardiography, Transesophageal
Female
Humans
Incidence
Intracranial Embolism - diagnostic imaging
Intracranial Embolism - epidemiology
Male
Prosthesis Design
Randomized Controlled Trials as Topic
Registries
Retrospective Studies
Risk Assessment
Risk Factors
Stroke - diagnostic imaging
Stroke - epidemiology
Thrombosis - diagnostic imaging
Thrombosis - epidemiology
Time Factors
Treatment Outcome
Title Device-Related Thrombus After Left Atrial Appendage Closure: Incidence, Predictors, and Outcomes
URI https://www.ncbi.nlm.nih.gov/pubmed/29752398
https://www.proquest.com/docview/2038268494
Volume 138
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 1524-4539
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0006375
  issn: 0009-7322
  databaseCode: KQ8
  dateStart: 19500101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 1524-4539
  dateEnd: 20240930
  omitProxy: true
  ssIdentifier: ssj0006375
  issn: 0009-7322
  databaseCode: DIK
  dateStart: 19500101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVFQY
  databaseName: GFMER Free Medical Journals
  customDbUrl:
  eissn: 1524-4539
  dateEnd: 20240930
  omitProxy: true
  ssIdentifier: ssj0006375
  issn: 0009-7322
  databaseCode: GX1
  dateStart: 19500101
  isFulltext: true
  titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php
  providerName: Geneva Foundation for Medical Education and Research
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1tb9MwELbKkCYmhGDjpbzJkxBftoy8OInDt6oFFTpAQCvtW4hde526JlWbgOAX8LM523mrtonBl6hym3Pbe3y5s5-7Q-iFDCOZUEEtIl1mEcaIxWBBWj4Yy5D5jpxONUH2YzCckPcn_kmn87vFWipydsR_XZpX8j9ahTHQq8qS_QfN1kJhAF6DfuEKGobrtXQ8EGqdW5rQBo7jeLbKFqxYH_R04-9joYrjmrYc4GwKCL5PxUH_PFObgmonAGyDaSmqXcmVOrJRvXcqQuenIocvXXIMq2IGZyteNvy6rI9Pa19hUMznmq6t91fVOdH3ZN3QE0eG2P01OWNJTfJo8iM01b759CBbz4ygmVjO4PeM2rsVjqp-XWV_i9LCusQivqlgVJtgj7awFrUMKjU9fC4a-kAZ-v67L_3JsSkbPOzBKD1SJ6WmAWkLAMuFRoDKIlb1DptnX81IrN66gW66YRCoXhijz03d-cAL_W20X8786sp5VW3pUtKmo3MhetlBt39kihCxnut8iJZXM76L7pThCO4ZbN1DHZHuor1emuTZ4id-iTVBWJ-87KLtDyUPYw9920QerpCHNfKwQh42yMM18nCJvNe4xt0hblB3iAFzuMLcfTR5-2bcH1plrw6Le-CkWokrbfBs2NQjNpOe4KGQ4P1FDkkczgWVxLeJmLpeAg4z9yVnEElHjhRSMJtK6T1AW2mWikcIc-ITCYGybbOAhCyiNBEOZy5IcUEG6yJa_bExLwvZq34q57EOaAMn3lQPjNHYqKeL3PrWpanmcp2b9ivtxWB71YFakoqsWMeu7VFVLSkiXfTQqLUWW8Ggi4INPccmv_nv0z6-UuQTdKtZWk_RVr4qxDNwjXP2XKP2DyZ0scg
linkProvider Colorado Alliance of Research Libraries
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Device-Related+Thrombus+After+Left+Atrial+Appendage+Closure%3A+Incidence%2C+Predictors%2C+and+Outcomes&rft.jtitle=Circulation+%28New+York%2C+N.Y.%29&rft.au=Dukkipati%2C+Srinivas+R&rft.au=Kar%2C+Saibal&rft.au=Holmes%2C+David+R&rft.au=Doshi%2C+Shephal+K&rft.date=2018-08-28&rft.eissn=1524-4539&rft.volume=138&rft.issue=9&rft.spage=874&rft_id=info:doi/10.1161%2FCIRCULATIONAHA.118.035090&rft_id=info%3Apmid%2F29752398&rft.externalDocID=29752398
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0009-7322&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0009-7322&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0009-7322&client=summon